Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00462358
Status:
COMPLETED
Last Update Posted:
2020-09-28
First Post:
2007-04-18
Brief Title:
A Study of ARRY-520 in Patients With Advanced Cancer
Sponsor:
Array Biopharma now a wholly owned subsidiary of Pfizer
Organization:
Array BioPharma
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-520
This study has two parts In the first part patients with advanced solid tumors will receive increasing doses of study drug with or without granulocyte-colony stimulating factor G-CSF support in order to achieve the highest dose possible that will not cause unacceptable side effects Approximately 15 patients per schedule from the US will be enrolled in Part 1 Completed
In the second part of the study patients will receive the best dose of study drug determined from the first part of the study and will be followed to evaluate what side effects the study drug causes and what effectiveness it has if any in treating the cancer Approximately 15 patients from the US will be enrolled in Part 2 Completed
This study has two parts In the first part patients with advanced solid tumors will receive increasing doses of study drug with or without granulocyte-colony stimulating factor G-CSF support in order to achieve the highest dose possible that will not cause unacceptable side effects Approximately 15 patients per schedule from the US will be enrolled in Part 1 Completed
In the second part of the study patients will receive the best dose of study drug determined from the first part of the study and will be followed to evaluate what side effects the study drug causes and what effectiveness it has if any in treating the cancer Approximately 15 patients from the US will be enrolled in Part 2 Completed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None